Overview

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Status:
Withdrawn
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of ARQ761 and a PARP inhibitor, Olaparib
Phase:
Phase 1
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Treatments:
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors